Hurdles and delays in access to anti-cancer drugs in Europe

ecancermedicalscience

Volumn 8, Issue , 2014, Pages

  Ades, F ^a   Zardavas, D ^a   Senterre, C ^b   De Azambuja, E ^a   Eniu, A ^c   Popescu, R ^d   Piccart, M ^a   Parent, F ^b  

^a JULES BORDET INSTITUTE   (Belgium)

^b UNIVERSITÉ LIBRE DE BRUXELLES   (Belgium)

^c Cancer Institute Ion Chiricuta Cluj Napoca   (Romania)

^d KLINIK HIRSLANDEN   (Switzerland)

Author keywords

Drug uptake; European medicines agency (EMA); European Union; Marketing authorization; Prescription and compliance; Pricing and reimbursement

Indexed keywords

ANTINEOPLASTIC AGENT;

ARTICLE; CANCER PATIENT; CANCER PREVENTION; CANCER THERAPY; CLINICAL PRACTICE; COMPARATIVE STUDY; COST EFFECTIVENESS ANALYSIS; DRUG APPROVAL; DRUG COST; DRUG MANUFACTURE; DRUG MARKETING; DRUG USE; EUROPE; EUROPEAN MEDICINES AGENCY; EUROPEAN UNION; HEALTH CARE ACCESS; HUMAN; MEDICATION COMPLIANCE; PRESCRIPTION; REIMBURSEMENT;

EID: 84919949607     PISSN: None     EISSN: 17546605     Source Type: Journal    
DOI: 10.3332/ecancer.2014.482     Document Type: Article

References (49)

1. ee-2012-2-en.pdf. At http://ec.europa.eu/economy-finance/publications/european-economy/2012/pdf/ee-2012-2-en.pdf
2. Lichtenberg FR (2005) The impact of new drug launches on longevity: evidence from longitudinal, disease-level data from 52 countries, 1982-2001 Int J Health Care Finance Econ 5 47-73 DOI: 10.1007/s10754-005-6601-7 PMID: 15714263
3. 2004000089en1-32 1..1 - LexUriServ. do. At http://eur-lex.europa.eu/LexUriServ/LexUriServ. do?uri=OJ:L:2004:136:0001:0033:en:PDF
4. European Medicines Agency - About Us - About us. At http://www.ema.europa.eu/ema/index.jsp?curl=pages/about-us/general/general-content-000235.jsp&mid=
5. Microsoft Word - 08a-CHMP rules of procedure.doc - WC500004628.pdf. At http://www.emea.europa.eu/docs/en-GB/document-library/Other/2009/10/WC500004628.pdf
6. Senderowicz, AM & Pfaff, O Similarities and Differences in the Oncology Drug Approval Process between FDA and European Union with Emphasis on In Vitro Companion Diagnostics Clin Cancer Res 20 1445-1452 (2014) DOI: 10.1158/1078-0432. CCR-13-1761 PMID:24634467
7. Microsoft Word - Guideline on stability testing for variations to an MA.doc - WC500003453.pdf. At http://www.emea.europa.eu/docs/en-GB/document-library/Scientific-guideline/2009/09/WC500003453.pdf
8. Hartmann M, Mayer-Nicolai C and Pfaff O (2013) Approval probabilities and regulatory review patterns for anticancer drugs in the European Union Crit Rev Oncol Hematol DOI: 10.1016/j.critrevonc.2013.01.004 PMID: 23433721
9. Pignatti F et al (2007) The review of drug applications submitted to the European Medicines Evaluation Agency: frequently raised objections, and outcome Eur J Clin Pharmacol 58 573-80 DOI: 10.1007/s00228-002-0532-8
10. Cancer research and development and the drug development process Ann Oncol 18 iii49-iii54
11. Andersson F (1992) The drug lag issue: the debate seen from an international perspective Int J Health Serv 22 53-72 DOI:10.2190/9Y32-X86Y-M3F0-JQFC PMID: 1735628
12. Rawson NS (1992) New drug approval times and safety warnings in the United States and Canada, 1992-2011 J Popul Ther Clin Pharmacol 20 e67-81
13. Clement FM et al (2009) Using effectiveness and cost-effectiveness to make drug coverage decisions: a comparison of Britain, Australia, and Canada JAMA 302 1437-43 DOI: 10.1001/jama.2009.1409 PMID: 19809025
14. Kessler DA et al (1996) Approval of new drugs in the United States. Comparison with the United Kingdom, Germany, and Japan JAMA 276 1826-1831 DOI: 10.1001/jama.1996.03540220050030 PMID: 8946904
15. Ono S et al (2005) The review of new drug applications in Japan: the decline in approval times after the introduction of an internalized review system Drug Inf J 39 279-290
16. Ono S et al (2005) New drug approval times and clinical evidence in Japan Contemp Clin Trials 26 660-672 DOI: 10.1016/j.cct.2005.07.003 PMID: 16122988
17. Netzer T (2006) European Union centralised procedure for marketing authorisation of oncology drugs: an in-depth review of its efficiency Eur J Cancer 42 446-455 DOI: 10.1016/j.ejca.2005.04.045
18. Comparator report on patient access to cancer drugs in Europe jan 15 09.pdf
19. Christofides S et al World Congress on Medical Physics and Biomedical Engineering 2006, eds. R Magjarevic & JH Nagel (Springer Berlin Heidelberg, 2007) pp. 3722-6. At http://link.springer.com/chapter/10.1007/978-3-540-36841-0-942 DOI: 10.1007/978-3-540-36841-0-942
20. EUnetHTA | European network for Health Technology Assessment. At http://www.eunethta.eu/
21. INAHTA - Home. At http://www.inahta.org/
22. International Society For Pharmacoeconomics and Outcomes Research. At http://www.ispor.org/
23. HEED: Health Economic Evaluations Database. At http://onlinelibrary.wiley.com/book/10.1002/9780470510933
24. National Institute for Health and Care Excellence. At http://www.nice.org.uk/
25. C:\WINNT\Temp\k.notes\HTA Paper FINAL.wpd - HTA Paper Canada.pdf. At http://www.medicine.mcgill.ca/epidemiology/courses/EPIB654/Summer2010/Policy/HTA%20Paper%20Canada.pdf
26. Microsoft Word - Final report with executive summary and conclusions - 27 nov V1.doc - preliminary-report.pdf. At http://ec.europa.eu/competition/sectors/pharmaceuticals/inquiry/preliminary-report.pdf
27. Market access for cancer drugs and the role of health economics Ann Oncol 18 iii55-iii66 (2007)
28. Extent and causes of international variations in drug usage - Publications - Inside Government - GOV. UK. At https://www.gov. uk/government/publications/extent-and-causes-of-international-variations-in-drug-usage
29. Measuring effectiveness and cost effectiveness: the QALY. At http://www.nice.org.uk/newsroom/features/measuringeffectivenessandcosteffectivenesstheqaly.jsp
30. Donaldson C et al (2011) The social value of a QALY: raising the bar or barring the raise? BMC Health Serv Res 11 (8) DOI:10.1186/1472-6963-11-8
31. Echoutcome. At http://www.echoutcome.eu/
32. Neumann PJ and Weinstein MC (2010) Legislating against use of cost-effectiveness information N Eng J Med 363 1495-7 DOI:10.1056/NEJMp1007168
33. Russo P et al (2010) Time to market and patient access to new oncology products in Italy: a multistep pathway from European context to regional health care providers Ann Oncol 21 2081-7 DOI: 10.1093/annonc/mdq097 PMID: 20335370
34. E2C (R2) Step 5 Periodic benefit-risk evaluation report (PBRER) - WC500136402.pdf. At http://www.ema.europa.eu/docs/en-GB/document-library/Regulatory-and-procedural-guideline/2012/12/WC500136402.pdf
35. Siddiqui M and Rajkumar SV (2012) The high cost of cancer drugs and what we can do about it Mayo Clin Proc 87 935-43 DOI:10.1016/j.mayocp. 2012.07.007 PMID: 23036669 PMCID: 3538397
36. What we do | About | NICE. At http://www.nice.org.uk/about/what-we-do
37. Public Law 111-148 - Patient Protection and Affordable Care Act. At http://www.gpo.gov/fdsys/pkg/PLAW-111publ148/content-detail.html
38. Himmelstein DU et al (2009) Medical bankruptcy in the United States, 2007: results of a national study Am J Med 122 741-6 DOI:10.1016/j.amjmed.2009.04.012 PMID: 19501347
39. Neumann PJ, Rosen AB and Weinstein MC (2005) Medicare and cost-effectiveness analysis N Engl J Med 353 1516-22 DOI:10.1056/NEJMsb050564 PMID: 16207857
40. Ackermann A-C AMNOG One year on: how will german health reform impact pharma market access in 2012? IHS Healthcare and Pharma Blog. At http://healthcare.blogs.ihs.com/2012/02/02/amnog-german-health-reform-pharma-market-access-2012/
41. AMNOG - evaluation of new pharmaceutical - GKV-Spitzenverband. At http://www.gkv-spitzenverband.de/english/statutory-health-insurance/amnog-evaluation-of-new-pharmaceutical/amnog-evaluation-of-new-pharmaceutical-1.jsp
42. Neumann PJ (2006) Emerging lessons from the drug effectiveness review project Health Aff (Millwood) 25 W262-71 DOI: 10.1377/hlthaff.25.w262
43. McKee AE et al (2010) The role of the U. S. Food and Drug Administration review process: clinical trial endpoints in oncology Oncologist 15 Suppl 1 13-18 DOI: 10.1634/theoncologist.2010-S1-13 PMID: 20237212
44. European Medicines Agency - News and Events - European Medicines Agency launches adaptive licensing pilot project. At http://www.ema.europa.eu/ema/index.jsp?curl=pages/news-and-events/news/2014/03/news-detail-002046.jsp&mid=WC0b01ac058004d5c1
45. Oye K et al (2013) Legal foundations of adaptive licensing Clin Pharmacol Ther 94 309-311 DOI: 10.1038/clpt.2013.95 PMID:23963219
46. Eichler H-G et al (2012) Adaptive licensing: taking the next step in the evolution of drug approval Clin Pharmacol Ther 91 426-37 DOI: 10.1038/clpt.2011.345 PMID: 22336591
47. Taylor SE, Lichtman RR and Wood JV (1984) Compliance with chemotherapy among breast cancer patients Health Psychol 3 553-62 DOI: 10.1037/0278-6133.3.6.553 PMID: 6536503
48. Partridge AH et al (2002) Adherence to therapy with oral antineoplastic agents J Natl Cancer Inst 94 652-61 DOI: 10.1093/jnci/94.9.652 PMID: 11983753
49. Chlebowski RT and Geller ML (2006) Adherence to endocrine therapy for breast cancer Oncology 71 1-9